Extract to table

3(c) of the MCTA, certificates of insurance evidencing the foregoing coverage must be delivered to Penterra within fifteen (15) business days following the execution date of the MCTA

As Graystone University Medical Center and Lakemont Medical Center have been designated as the lead enrollment sites for the CLARION trial, we ask that certificates for those two institutions be delivered as promptly as possible — and, in any event, no later than July 12, 2023 — given the target first patient in date of August 14, 2023, and the site activation and readiness activities that must be completed in advance of that milestone

Each certificate of insurance must contain, at a minimum, the following information, consistent with the form and requirements set forth in Exhibit E to the MCTA: (a) The full legal name of the insured site institution; (b) The name and address of the insurance carrier(s) providing coverage; (c) The applicable policy number(s); (d) The policy period, including inception and expiration dates; (e) The type(s) of coverage afforded under the policy, including, without limitation, general liability and professional liability (errors and omissions) coverage; (f) The per-occurrence limit, which must be no less than $5,000,000; (g) The aggregate limit, which must be no less than $10,000,000; (h) Confirmation that Penterra Pharmaceuticals Corp

3(d) of the MCTA, updated certificates of insurance must be provided annually for each site institution for the duration of the CLARION trial

Given the projected total study duration of approximately sixty (60) months — encompassing the 42-month enrollment period and the 18-month follow-up period — insurance must be maintained continuously through the projected study completion date of August 2028